Engine Alliance Selects CTS Engines to Provide MRO Engine Services for the GP7200
CTS Engines (CTS) announces they have been selected to provide MRO services for Engine Alliance (EA) on the GP7200 turbofan jet engine. EA is a 50-50 joint venture between Pratt & Whitney and General Electric for the development, production, and service of the GP7200. The GP7200 is the premier engine for the A380 aircraft as it combines the reliability and ingenuity of the PW4000 and GE90 engines while providing the most fuel-efficient and quietest powerplant for the A380.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230524005295/en/
Engine Alliance selects CTS Engines to provide MRO Engine Services for the GP7200 (Graphic: Business Wire)
“In 2019, Engine Alliance changed its operational focus to aftermarket services and customer support. The partnership with CTS will help us meet our customers’ high expectations,” said Amy Johnston, President of EA. “CTS leadership team provides a unique perspective that comes from years of experience at airlines, MRO shops, and the OEMs, and we are confident CTS will deliver the results our airline customers require,” stated Johnston.
“We are excited to partner with EA to provide MRO services for the GP7200. This is a fantastic opportunity for us to learn the best practices from the world’s greatest engine companies while also delivering world-class quality, reliability, and turnaround time,” said Vesa Paukkeri, Chief Executive Officer of CTS.
About CTS Engines
CTS Engines is a global leader in mature engine maintenance, rethinking business as usual. Based in Fort Lauderdale, FL, CTS Engines is an independent MRO providing complete maintenance, repair, overhaul, and testing services to owners and operators of mature wide-body aircraft engines. We proudly support a wide range of both commercial and military customers. Since 2002, CTS Engines has built its reputation on the ability to provide its customers with high-quality, cost-effective solutions for engine maintenance. Our mission is to keep our customers’ mature engines flying longer and more reliably than any other MRO in the world.
About Engine Alliance
Engine Alliance (EA) is a 50-50 joint venture of GE (NYSE:GE) and Pratt & Whitney (P&W), a Raytheon Technologies business (NYSE:RTX). Revenue-sharing partners include MTU Aero Engines of Germany, SAFRAN Aero Boosters of Belgium and SAFRAN Aircraft Engines of France. EA manufactures and services the quietest, most reliable and most fuel-efficient powerplant for the A380, the GP7200.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005295/en/
Contact information
For more information, press only:
CTS Engines
Alejandra Meza
AMeza@ctsengines.com
For more information on CTS Engines please visit our website:
www.CTSEngines.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Group Enters the Thai Market through Partnership with BLEZ14.11.2025 14:47:00 EET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced that it has entered into a Consulting Agreement with BLEZ ASIA Co., Ltd. (Headquarters: Bangkok, Thailand; CEO: Naoki Iida; “BLEZ”), which operates more than 20 pharmacies and clinics in Thailand and is widely trusted by both Japanese expatriates and local patients. The partnership is a key component of SBC’s broader Asia strategy and represents a significant step toward full-scale entry into the rapidly growing Thai aesthetic medicine market. Under the agreement, SBC will provide comprehensive management support to a new clinic focused primarily on dermatological treatments such as pigmentation and spot removal, which BLEZ is preparing to open in Bangkok. SBC will advise on clinical protocol development, aligned with SBC’s quality standards, and assist in selecting me
SBC Medical Group Holdings Announces Third Quarter 2025 Financial Results14.11.2025 14:00:00 EET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced its financial results for the third quarter of fiscal year 2025 (three months ended September 30, 2025) and for the third quarter cumulative of fiscal year 2025 (Year-to-Date 2025, nine months ended September 30, 2025) Third Quarter 2025 Highlights Total revenues were $43 million, representing an 18% year-over-year decrease. Income from operations was $16 million, representing a 15% year-over-year increase. Net Income attributable to SBC Medical Group was $13 million , representing an 353% year-over-year increase. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.12 for the three months ended September 30, 2025, compared to $0.03 in the same period of 2024. EBITDA1, which
Ant Group Chairman Eric Jing Outlines Strategy for Inclusive AI, Collaboration on Tokenised Settlement14.11.2025 12:15:00 EET | Press release
Eric Jing, Chairman of Ant Group, said the company's focus is on putting new payment and operation tools powered by AI and tokenisation technology in the hands of SMEs, to fully embrace the next wave of global productivity revolution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251114239737/en/ Ant Group Chairman Eric Jing (second from right) shares insights during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on November 14, 2025. “We are passionate about using frontier technology to support SMEs and the use of AI will really uplift inclusion,” Jing said during a panel discussion titled “Steering the Global Future” during the Singapore FinTech Festival on November 14, 2025. Jing was joined by Agustín Carstens, Former General Manager, Bank for International Settlements (BIS); Ravi Menon, Chairman of the Board of Directors, Global Finance & Technology Network (GFTN); Ambassado
Allianz Achieves Record Results and Expects a Full-Year Operating Profit of at Least 17 Billion Euros14.11.2025 08:16:00 EET | Press release
3Q 2025 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251113803211/en/ Oliver Bäte, Chief Executive Officer of Allianz SE Double-digit growth in operating profit and shareholders’ core net incomeTotal business volume rises 5.21 percent with contributions from all segments Operating profit increases 12.6 percent to 4.4 billion euros, with particular strong contribution from the Property-Casualty segment Shareholders’ core net income advances by 12.7 percent and reaches 2.9 billion euros 9M 2025 Continued strong and diversified growth across our businessesand record operating profitTotal business volume rises 8.5 1 percent and reaches 141.2 billion euros with contributions from all segments Operating profit increases 10.4 percent to 13.1 billion euros, our highest nine-month operating profit ever, reaching 82 percent of our full-year outlook midpoint Shareholders’ core net income advances 10.5 percent to 8.4 billion euros. Ad
Galderma Completes Successful Placement of CHF 175 Million Bond14.11.2025 08:00:00 EET | Press release
NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the successful placement of a single-tranche CHF 175 million Swiss franc-denominated bond. The bond has a maturity of 5 years and carries a fixed-rate annual coupon of 0.9425%. Net proceeds from the transaction will be used to partially refinance Galderma’s existing bank term loan issued at its initial public offering (IPO) in March 2024, as well as for general corporate purposes. This marks the company’s third CHF-bond issuance since listing. The new bond will be listed on the SIX Swiss Exchange, with the settlement date expected on December 10, 2025. BNP Paribas and UBS jointly led the transaction. Galderma is rated BBB (stable outlook) by Fitch. The same rating is also expected to be assigned to the new bond. The successful issuance is leverage-ne
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom